首页> 外文期刊>The American journal of Chinese medicine >Traditional chinese medicine injection for angina pectoris: An overview of systematic reviews
【24h】

Traditional chinese medicine injection for angina pectoris: An overview of systematic reviews

机译:心绞痛的中药注射剂:系统评价概述

获取原文
获取原文并翻译 | 示例
       

摘要

Traditional Chinese medicine (TCM) injection is widely used to treat angina pectoris in China. This overview aims to systematically summarize the general characteristics of systematic reviews (SRs) on TCM injection in treating angina, and assess the methodological and reporting quality of these reviews. We searched PubMed, Embase, the Cochrane Library and four Chinese databases from inception until March 2013. Data were extracted according to a preset form. The AMSTAR and PRISMA checklists were used to explore the methodological quality and reporting characteristics of included reviews, respectively. All data analyses were descriptive. 46 SRs involving over 57,463 participants with angina reviewing 23 kinds of TCM injections were included. The main outcomes evaluated in the reviews were symptoms (43/46, 93.5%), surrogate outcomes (42/46, 91.3%) and adverse events (41/46, 87.0%). Few reviews evaluated endpoints (7/46, 15.2%) and quality of life (1/46, 2.2%). One third of the reviews (16/46, 34.8%) drew definitely positive conclusions while the others (30/46, 65.2%) suggested potential benefits mainly in symptoms, electrocardiogram and adverse events. With many serious flaws such as lack of a protocol and inappropriate data synthesis, the overall methodological and reporting quality of the reviews was limited. While many SRs of TCM injection on the treatment of angina suggested potential benefits or definitely positive effects, stakeholders should not accept the findings of these reviews uncritically due to the limited methodological and reporting quality. Future SRs should be appropriately conducted and reported according to international standards such as AMSTAR and PRISMA, rather than published in large numbers.
机译:中药注射液在中国被广泛用于治疗心绞痛。本概述旨在系统总结中药治疗心绞痛的系统评价(SR)的一般特征,并评估这些评价的方法学和报告质量。从开始到2013年3月,我们搜索了PubMed,Embase,Cochrane图书馆和四个中文数据库。数据是按照预设格式提取的。 AMSTAR和PRISMA清单分别用于探讨纳入评价的方法学质量和报告特征。所有数据分析均为描述性。包括46个SR,涉及超过57,463名参与者,其中有心绞痛回顾了23种中药注射剂。评估中评估的主要结局为症状(43/46,93.5%),替代结局(42/46,91.3%)和不良事件(41/46,87.0%)。很少有评论评估终点(7 / 46,15.2%)和生活质量(1 / 46,2.2%)。三分之一的评论(16 / 46,34.8%)得出肯定肯定的结论,而其他评论(30 / 46,65.2%)则表明潜在的益处主要在症状,心电图和不良事件方面。由于存在许多严重缺陷,例如缺乏协议和不适当的数据合成,因此,评论的总体方法和报告质量受到限制。尽管许多中药注射液治疗心绞痛的SR均显示出潜在的益处或肯定的积极作用,但由于方法和报告质量有限,利益相关者不应不加批判地接受这些评价的结果。未来的SR应根据AMSTAR和PRISMA等国际标准进行适当地执行和报告,而不是大量发布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号